Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the planned acquisition of Orna Therapeutics and a new large-scale strategic ...
Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...
After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation ...
In his post, Makary said, “FDA will take swift action against companies’ mass-marketing illegal copycat drugs, claiming they ...
FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...
In a lean biotech environment with aggressive milestones, teams often accept reporting that is “good enough.” But those ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results